Editorial
dc.contributor.author | Oral, Timuçin | |
dc.date.accessioned | 2024-10-12T19:47:13Z | |
dc.date.available | 2024-10-12T19:47:13Z | |
dc.date.issued | 2014 | |
dc.department | İstanbul Ticaret Üniversitesi | en_US |
dc.description.abstract | [No abstract available] | en_US |
dc.identifier.issn | 1300-0667 | |
dc.identifier.issue | 1 | en_US |
dc.identifier.scopus | 2-s2.0-84897098641 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.uri | https://hdl.handle.net/11467/8814 | |
dc.identifier.volume | 51 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.language.iso | en | en_US |
dc.publisher | Turkish Neuropsychiatric Society | en_US |
dc.relation.ispartof | Noropsikiyatri Arsivi | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.snmz | Scopus_20241012 | en_US |
dc.subject | carbamazepine | en_US |
dc.subject | lithium carbonate | en_US |
dc.subject | lithium salt | en_US |
dc.subject | valproic acid | en_US |
dc.subject | article | en_US |
dc.subject | bipolar disorder | en_US |
dc.subject | body weight disorder | en_US |
dc.subject | disease severity | en_US |
dc.subject | drug absorption | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | drug elimination | en_US |
dc.subject | drug safety | en_US |
dc.subject | drug tolerability | en_US |
dc.subject | human | en_US |
dc.subject | hypothyroidism | en_US |
dc.subject | iodination | en_US |
dc.subject | kidney failure | en_US |
dc.subject | morbidity | en_US |
dc.subject | mortality | en_US |
dc.subject | prevalence | en_US |
dc.subject | recurrent disease | en_US |
dc.subject | risk assessment | en_US |
dc.subject | risk factor | en_US |
dc.subject | thyroid disease | en_US |
dc.subject | thyroid function test | en_US |
dc.subject | weight gain | en_US |
dc.title | Editorial | en_US |
dc.title.alternative | Editörden | en_US |
dc.type | Article | en_US |